大动脉炎合并脑梗死49例临床分析

doi:10.3969/j.issn.1673-5765.2020.12.009

摘要/Abstract

摘要：

目的总结大动脉炎合并脑梗死患者的临床特点，分析此类患者脑梗死复发的相关因素。方法回顾性分析2010年1月-2020年6月随访超过3年的大动脉炎合并脑梗死患者的临床资料，对此类患者脑梗死复发的相关因素进行分析。结果共纳入49例患者，首次脑梗死中位年龄30.0（22.0～45.0）岁，中位随访时间3.4（3.2～3.7）年。 11例（22.4%）出现复发性脑梗死，两次脑梗死间隔中位时间8.0（5.0～88.0）个月。与脑梗死无复发患者相比，复发性脑梗死患者合并糖尿病比例（27.3% vs 2.6%，P =0.031）以及首次脑梗死后随访期间平均TG水平（3.65±0.96 mmol/L vs 1.14±0.54 mmol/L，P =0.001）升高。大动脉炎受累动脉以颈总动脉最为常见（48/49，98%），其次是椎动脉（40/49，81.6%），受累血管病变性质以狭窄（49/49， 100%）和闭塞（36/49，73.5%）最常见。脑梗死复发组动脉闭塞比例（100% vs 65.8%，P =0.024）和动脉血栓发生率（45.5% vs 13.2%，P =0.033）均高于脑梗死无复发组。治疗方面，脑梗死复发组抗血小板治疗患者比例（63.6% vs 97.4%，P =0.007）及接受血管重建术的患者比例（27.3% vs 68.4％， P =0.033）均低于脑梗死无复发组。结论大动脉炎合并脑梗死的患者，如合并糖尿病、血脂控制欠佳、主动脉弓分支动脉有闭塞、血栓形成者，脑梗死复发风险高。

文章导读： 通过回顾性分析发现大动脉炎合并脑梗死患者中，合并糖尿病、脂代谢紊乱、大动脉闭塞和狭窄可能是脑梗死复发的危险因素，而抗凝/抗血小板治疗及血管重建术的患者脑梗死复发的风险较低。

关键词: 大动脉炎; 脑梗死; 复发

Abstract:

Objective To summarize the clinical features of Takayasu arteritis (TA) complicated with cerebral infarction (CI), and analyze the related factors for recurrent cerebral infarction in TA patients. Methods The clinical data of 49 patients with TA and CI who were followed up for more than 3 years from January 2010 to June 2020 were retrospectively analyzed. Results A total of 49 eligible patients were included. The median age at the first CI onset was 30.0 (22.0-45.0) years old, and the median follow-up time was 3.4 (3.2-3.7) years. Recurrent cerebral infarction occurred in 11 cases (22.4%), and the median time between the two CI was 8.0 (5.0-88.0) months. The proportion of diabetes mellitus (27.3% vs 2.6%, P =0.031) and the elevated triglyceride level during the follow-up after CI (3.65±0.96 mmol/L vs 1.14±0.54 mmol/L, P =0.001) in patients with recurrent CI were significantly higher than that in those without recurrent CI. The most involved artery in TA was common carotid artery (48/49, 98%), followed by vertebral artery (40/49, 81.6%), stenosis (49/49, 100%) and occlusion (36/49, 73.5%) were the most common lesions in these involved arteries. The incidence of artery occlusion (100% vs 65.8%, P =0.024) and thrombosis (45.5% vs 13.2%, P =0.033) in patients with recurrent CI were significantly higher than that in those without recurrent CI. The patients with recurrent CI had lower proportion of receiving antiplatelet therapy (63.6% vs 97.4%, P =0.007) and revascularization (27.3% vs 68.4%, P =0.033) than those without recurrent CI. Conclusions Diabetes mellitus, poor lipid control, occlusion in branches of aortic arch and thrombosis were correlated with recurrent CI risk in patients with TA and CI.

Key words: Takayasu arteritis; Cerebral infarction; Recurrence

孔芳，黄旭，魏廉，苏丽，廖秋菊，刘宏军，赵义. 大动脉炎合并脑梗死49例临床分析[J]. 中国卒中杂志, 2020, 15(12): 1306-1312.

KONG Fang, HUANG Xu, WEI Lian, SU Li, LIAO Qiu-ju, LIU Hong-Jun, ZHAO Yi. Clinical Analysis of 49 Cases of Takayasu Arteritis Complicated with Cerebral Infarction[J]. Chinese Journal of Stroke, 2020, 15(12): 1306-1312.

参考文献

[1] RINGLEB P A，STRITTMATTER E I，LOEWER

M，et al. Cerebrovascular manifestations of

Takayasu arteritis in Europe[J]. Rheumatology

（Oxford），2005，44（8）：1012-1015.

[2] YANG L R，ZHANG H M，JIANG X J，et

al. Clinical features and outcomes of Takayasu

arteritis with neurological symptoms in China：a

retrospective study[J]. J Rheumatol，2015，42（10）：

1846-1852.

[3] DE PAULA L E，ALVERNE A R，SHINJO S K.

Clinical and vascular features of Takayasu arteritis

at the time of ischemic stroke[J]. Acta Reumatol Port，

2013，38（4）：248-251.

[4] MAEDA Y，TAGUCHI H，KUDO T，et al. Takayasu

arteritis and ischaemic stroke[J]. QJM，2016，109

（1）：45-46.

[5] HWANG J，KIM S J，BANG O Y，et al. Ischemic

stroke in Takayasu's arteritis：lesion patterns and

possible mechanisms[J]. J Clin Neurol，2012，8（2）：

109-115.

[6] DUARTE M M，GERALDES R，SOUSA R，et al.

Stroke and transient ischemic attack in Takayasu's

arteritis：a systematic review and meta-analysis[J]. J

Stroke Cerebrovasc Dis，2016，25（4）：781-791.

[7] PFEFFERKORN T，BITTERLING H，HUFNER K，

et al. Malignant hemispheric infarction in Takayasu

arteritis[J]. J Neurol，2008，255（9）：1425-1426.

[8] COUTURE P，CHAZAL T，ROSSO C，et al.

Cerebrovascular events in Takayasu arteritis：a

multicenter case-controlled study[J]. J Neurol，2018，265（4）：757-763.

[9] 董丽，林霞，葛建文，等. 多发性大动脉炎合并脑梗

死研究进展[J]. 中国现代医生，2017，55（20）：165-

168.

[10] AREND W P，MICHEL B A，BLOCH D A，et

al. The American College of Rheumatology 1990

criteria for the classification of Takayasu arteritis[J].

Arthritis Rheum，1990，33（8）：1129-1134.

[11] HATA A，NODA M，MORIWAKI R，et al.

Angiographic findings of Takayasu arteritis：new

classification[J/OL]. Int J Cardiol，1996，54（Suppl）：

S155-S163[2020-08-01]. https：//doi.org/10.1016/

s0167-5273（96）02813-6.

[12] KERR G S，HALLAHAN C W，GIORDANO J，et

al. Takayasu arteritis[J]. Ann Intern Med，1994，120

（11）：919-929.

[13] MISRA R，DANDA D，RAJAPPA S M，et al.

Development and initial validation of the Indian

Takayasu Clinical Activity Score（ITAS2010）[J].

Rheumatology（Oxford），2013，52（10）：1795-1801.

[14] TOMBETTI E，MASON J C. Takayasu arteritis：

advanced understanding is leading to new

horizons[J]. Rheumatology（Oxford），2019，58（2）：

206-219.

[15] EKKER M S，BOOT E M，SINGHAL A B，et

al. Epidemiology，aetiology，and management of

ischaemic stroke in young adults[J]. Lancet Neurol，

2018，17（9）：790-801.

[16] VIDHATE M，GARG R K，YADAV R，et al. An

unusual case of Takayasu's arteritis：evaluation by

CT angiography[J]. Ann Indian Acad Neurol，2011，

14（4）：304-306.

[17] BENAVENTE O，ELIASZIW M，STREIFLER J Y，

et al. Prognosis after transient monocular blindness

associated with carotid-artery stenosis[J]. N Engl J

Med，2001，345（15）：1084-1090.

[18] KUMRAL E，EVYAPAN D，AKSU K，et al.

Microembolus detection in patients with Takayasu's

arteritis[J]. Stroke，2002，33（3）：712-716.

[19] LIU Q，DANG A M，LV N Q，et al. Anaemia and

low body mass index are associated with increased

cardiovascular disease in patients with Takayasu

arteritis[J/OL]. Clin Exp Rheumatol，2016，34（3

Suppl 97）：S16-20[2020-08-01]. https：//www.

clinexprheumatol.org/abstract.asp?a=9266.

[20] TANG W H，YAO L，ROETKER N S，et al.

Lifetime risk and risk factors for abdominal aortic

aneurysm in a 24-year prospective study：the ARIC

study（Atherosclerosis Risk in Communities）[J].

Arterioscler Thromb Vasc Biol，2016，36（12）：

2468-2477.

[21] PAN L L，DU J，CHEN D，et al. Takayasu arteritis

with dyslipidemia increases risk of aneurysm[J]. Sci

Rep，2019，9（1）：14083.

[22] CHEN M，REN L N，MENG Y Y，et al. The

protease inhibitor E64d improves ox-LDL-induced

endothelial dysfunction in human aortic endothelial

cells[J]. Can J Physiol Pharmacol，2018，96（2）：

120-127.

[23] MASON J C. Surgical intervention and its role in

Takayasu arteritis[J]. Best Pract Res Clin Rheumatol，

2018，32（1）：112-124.

[24] ROSA NETO N S，SHINJO S K，LEVY-NETO

M，et al. Vascular surgery：the main risk factor

for mortality in 146 Takayasu arteritis patients[J].

Rheumatol Int，2017，37（7）：1065-1073.

[25] PORTER A，YOUNGSTEIN T，TOMBETTI E，

et al. Biologic therapy in supra-aortic Takayasu

arteritis can improve symptoms of cerebral

ischaemia without surgical intervention[J/OL].

Rheumatology（Oxford），2020，59（Supplement_3）：

iii28-iii32[2020-08-01]. https：//doi.org/10.1093/

rheumatology/kez616.

[26] HELLMICH B，AGUEDA A，MONTI S，et al.

2018 Update of the EULAR recommendations for

the management of large vessel vasculitis[J]. Ann

Rheum Dis，2020，79（1）：19-30.